Treatment sequencing options for recurrent CLL

Michael Choi, MD, UC San Diego Health, San Diego, CA, discusses treatment options for patients with recurrent chronic lymphocytic leukemia (CLL). Patients who have severe side effects or have progressed from current BTK inhibitors can be treated with alternative BTK inhibitors such as acalabrutinib, which has fewer side effects and the same efficacy as ibrutinib, or non-covalent BTK inhibitors such as pirtobrutinib. Venetoclax, chimeric antigen receptor (CAR) T-cell therapy, and allogeneic stem cell transplant are additional treatments to be considered for patients who have progressed from existing therapies. This interview took place at the Lymphoma, Leukemia & Myeloma Congress 2021.